Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people on Wegovy notice their appetite beginning to fall within the first one to four weeks, but meaningful, measurable weight loss typically builds over three to six months as the dose increases. In the STEP 1 clinical trial, participants lost an average of around 15% of their body weight over 68 weeks at the 2.4mg maintenance dose. That headline figure tells part of the story; the fuller picture is that weight loss on Wegovy is gradual and dose-dependent, not instant. Wegovy (semaglutide) is a prescription-only medicine: a clinician must assess your suitability before treatment can begin, and the pace at which you lose weight will depend on several factors your prescriber can help you understand.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy starts at 0.25mg, a dose chosen to help your body adjust rather than to produce rapid weight loss. Nausea, mild digestive changes and reduced appetite are common at this stage. Some people notice the scales moving slightly in these early weeks, but this isn't where the bulk of progress happens, and that's by design.
The titration schedule moves upward roughly every four weeks, from 0.25mg through 0.5mg, 1mg and 1.7mg before reaching the standard 2.4mg maintenance dose. The pace is deliberate: rushing the schedule tends to worsen side effects without speeding up results. If you keep your pen in the fridge door as a reminder, you'll quickly find that dose-day becomes a quiet habit long before the numbers on the scale do anything dramatic.
The practical takeaway for these first two months: expect appetite changes, not a transformation. The treatment is working even when the weight loss feels modest. Many people find this phase the most testing, which is why clinical support through it is genuinely useful rather than optional.
Once you're at or approaching the 2.4mg maintenance dose, weight loss typically accelerates. If you've been wondering how long it takes to lose weight on Wegovy, this is the phase where most of that answer becomes visible. Across the STEP 1 trial (1,961 adults, 68 weeks, published in the New England Journal of Medicine) participants had lost roughly 8 to 10 percentage points of their body weight by the six-month mark, with losses continuing beyond that.
Individual variation here is real. Starting weight, how well gastrointestinal side effects are tolerated, diet quality and physical activity all shift the curve. Someone eating a high-protein, calorie-conscious diet alongside treatment will generally see stronger results than someone making no changes at all. The NHS advises that semaglutide should be used alongside a reduced-calorie diet and increased activity, not instead of them.
For a more detailed look at what drives the timing of early results, our page on when you can expect to lose weight on Wegovy breaks down the early weeks in more depth.
NICE guidance on semaglutide for weight management notes that if a patient hasn't lost at least 5% of their body weight after six months at the highest tolerated dose, the prescriber should review whether continuing is appropriate. That threshold is a clinical checkpoint, not a failure verdict, it reflects the evidence on who benefits most from long-term treatment.
For those who do respond well, weight loss continues beyond six months, often slowing into a plateau as the body reaches a new equilibrium. The average 15% figure from STEP 1 reflects 68 weeks of treatment; the newer Wegovy 7.2mg dose, approved by the MHRA in April 2026, showed around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide in head-to-head data. That higher dose isn't available to everyone and requires clinical assessment, but it narrows the gap considerably for those who are suitable.
NICE recommends semaglutide for weight management for a maximum of two years under its current appraisal (NICE TA875). Long-term use beyond that, or what happens to weight after stopping, are questions best put directly to your prescriber. Our page on how long you should take Wegovy covers the duration question in full.
Several factors consistently show up in trial data and clinical practice as having a meaningful effect on results. Dose tolerability is one: people who can't progress past 1mg because of persistent nausea tend to see more modest losses. Adherence matters significantly, missing doses disrupts the steady-state concentration the medicine needs to work consistently. Diet composition, particularly protein adequacy, helps protect muscle mass during weight loss. And sleep quality and stress have metabolic effects that no injection overcomes entirely.
Cost is a practical factor too. If you're wondering whether the price of private treatment is worth sustaining over the months required, our Wegovy cost guide sets out what private treatment typically involves and what a transparent price should include.
Weight loss on GLP-1 medicines like Wegovy is also discussed across our broader weight loss treatment overview, which sets Wegovy in context alongside other licensed options. For those curious how the timeline compares across medicines in the same class, the semaglutide weight loss timeline page covers that angle directly.
If you're ready to discuss whether Wegovy is clinically suitable for you, a free consultation with our prescribers is the next step. A real clinician reviews every application the same day, your answers go to a person, not an algorithm.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.